# Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Austria (REAL)

> **NCT02582658** · — · COMPLETED · sponsor: **AbbVie** · enrollment: 173 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02582658
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-06
- **Primary completion:** 2017-01-12
- **Final completion:** 2017-01-12
- **Target enrollment:** 173 (ACTUAL)
- **Last updated:** 2019-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02582658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02582658, "Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Austria (REAL)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02582658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*